SYK - Stryker Corporation
| Previous Close | 215.32 |
| Open | 215.60 |
| Bid | 210.44 x 1400 |
| Ask | 210.61 x 800 |
| Day's Range | 210.28 - 216.39 |
| 52 Week Range | 144.75 - 223.45 |
| Volume | 464,099 |
| Avg. Volume | 1,024,266 |
| Market Cap | 78.741B |
| Beta (3Y Monthly) | 1.01 |
| PE Ratio (TTM) | 22.52 |
| EPS (TTM) | 9.35 |
| Earnings Date | Oct 29, 2019 |
| Forward Dividend & Yield | 2.08 (0.97%) |
| Ex-Dividend Date | 2019-09-27 |
| 1y Target Est | 227.76 |
- Zacks
Medical Products Industry Outlook: Prospects Seem Promising
Medical Products Industry Outlook: Prospects Seem Promising
- GlobeNewswire
Stryker completes acquisition of Mobius Imaging and Cardan Robotics
Stryker (SYK) announced today it has completed the acquisition of Mobius Imaging, LLC, a leader in point-of-care imaging technology, and its sister company, GYS Tech, LLC (DBA Cardan Robotics). “Mobius Imaging and Cardan Robotics bring expertise in advanced imaging and robotics, as well as a robust product pipeline, that will provide Stryker the opportunity to increase its presence in Orthopaedics, Spine and Neurotechnology,” said Spencer Stiles, Stryker’s Group President, Orthopaedics and Spine.
- Zacks
Tandem Rides on Strong t:slim X2 Rollout Amid Stiff Rivalry
Tandem Diabetes (TNDM) gains on strong domestic sales along with a solid international rollout of the t:slim X2 insulin pump.
- Zacks
Align Rides on Volume Expansion Amid Poor Shipment Scenario
Align Technology (ALGN) is continuing with its winning streak of delivering a sturdy Invisalign Technology volume expansion across the company's entire customer base.
- Zacks
CHF Solutions System to be Used in JAHVH Study After Final Nod
CHF Solutions' (CHFS) Aquadex system to be used for the outpatient study on heart failure, conducted by James A. Haley Veterans' Hospital and Clinics. The study receives final approval.
- Zacks
Edwards Lifesciences Hits a 52-Week High on Solid Prospects
Edwards Lifesciences (EW) has been consistently delivering impressive results.
- Zacks
Here's Why You Should Retain Henry Schein (HSIC) Stock Now
Investor confidence is still high on Henry Schein (HSIC), thanks to solid prospects.
- Zacks
Phibro (PAHC) Suffers Dismal Segmental Sales, Margin Woes
Per Phibro Animal (PAHC), weak demand in Animal Health business due to swine flu outbreak in China along with an unfavorable product mix in Mineral Nutrition is dampening.
- Zacks
Penumbra Enrolls First Patient for Study on Coronary Vessels
Penumbra (PEN) gears up for the study of mechanical power aspiration as part of advancements in coronary treatment.
- Zacks
Thermo Fisher Gets a Boost from Buyouts and Global Expansion
Thermo Fisher (TMO) registers a solid international performance with strong growth in Europe and Asia-Pacific including China.
- Zacks
QIAGEN Down on Dim Q3 Prelim Sales, Startling CEO Departure
If the dismal preliminary sales performance was not enough, then the news pertaining to QIAGEN's (QGEN) current CEO Peer M. Schatz's stepping down came as another huge blow.
- Zacks
Here's Why You Should Add Stryker (SYK) to Your Portfolio Now
Stryker's (SYK) core Mako Platform has been consistently driving its top line.
- Zacks
Smith & Nephew's (SNN) STITCH Study Outcome Encouraging
This can be considered a major step in Smith & Nephew's (SNN) commitment toward strengthening its Global Sports Medicine and ENT segment.
- Zacks
Medtronic Submits Two Pelvic Health Devices for FDA's PMA
Medtronic's (MDT) filing for both its InterStim products to gain FDA's PMA is its essential bid to boost its Pelvic Health & Gastric Therapies business.
- Insider Monkey
Hedge Funds Dropped The Ball On Stryker Corporation (SYK)
World-class money managers like Ken Griffin and Barry Rosenstein only invest their wealthy clients' money after undertaking a rigorous examination of any potential stock. They are particularly successful in this regard when it comes to small-cap stocks, which their peerless research gives them a big information advantage on when it comes to judging their worth. […]
- Simply Wall St.
Introducing Stryker (NYSE:SYK), The Stock That Zoomed 162% In The Last Five Years
When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose...
- Zacks
Omnicell Advances on Global Footing Despite Severe Rivalry
Considering the weak penetration level in the international market, which is even less than 1%, Omnicell (OMCL) is rapidly exploring the uncharted overseas markets.
- Zacks
Medtronic Gets FDA's Breakthrough Device Nod for Valiant TAAA
This FDA designation is expected to bolster Medtronic's (MDT) Aortic, Peripheral & Venous line within the broader Cardiac and Vascular group.
- Zacks
Here's Why You Should Hold on to Teleflex (TFX) Stock Now
Investor confidence is still high on Teleflex (TFX), thanks to solid prospects.
- Zacks
Stryker Gains From Flagship Mako and Broad Product Spectrum
Stryker's (SYK) broad product spectrum cushions the company from any significant sales shortfall.
- Zacks
AngioDynamics (ANGO) Q1 Earnings Top, Revenues Lag Estimates
AngioDynamics (ANGO) keeps fiscal 2020 revenue guidance intact, slashes EPS view.
- Zacks
Tandem Diabetes' Inland Sales and Product Suite Are Tailwinds
Sturdy domestic sales along with a strong rollout of the t:slim X2 Insulin Pump in the international markets bode well for Tandem Diabetes (TNDM).
- Zacks
Here's Why You Should Hold on to Quest Diagnostics Stock Now
Investor confidence is high on Quest Diagnostics (DGX) stock, thanks to solid prospects.
- Zacks
Illumina, Broad Institute Partner on Secondary Genomic Analysis
The tie-up between Illumina (ILMN) and the Broad Institute of MIT and Harvard is expected to enhance the company's portfolio of sequencing products.
